HIV-1
Conditions
Brief summary
In this study, the investigators evaluated a therapeutic HIV-1 DNA vaccine administered with a novel topical application method to 12 chronically HIV-infected cART treated patients. The HIV DNA plasmids used in this study encode for envelope gp160 of HIV-1 subtypes A, B and C, rev B, Gag A and B and reverse transcriptase (RT) B. The patients were randomly assigned to three groups; group 1 (n=4) were immunized six times with 0.4 mg of HIV DNA plasmids topically, group 2 (n=4) were immunized six times with 0.4 mg of HIV DNA plasmids topically and treated with 500 mg of hydroxyurea daily until visit 10, group 3 (n=4) four patients received placebo. The immunization was performed during three cycles of 7 weeks of cART followed by four weeks of therapy interruption. After the last cycle of cART the patients were maintained on a definitive treatment interruption until CD4+ T cell counts dropped below 350/ mm3 at two time points. Cellular and humoral immune responses, viral load and CD4+ T a cell count was analysed throughout the study.
Interventions
BIOLOGICALHIV DNA Vaccine
0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
Sponsors
European Union
The Swedish Research Council
Läkare mot AIDS Forskningsfond
Swedish Institute for Infectious Disease Control
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Aged between 18 and 60 years 2. Female, who is documented infertile or in menopause since at least 1 year, or male, who are willing not father a child for the duration of the study. 3. HIV infection detected by two serological and/or HIV plasma RNA tests 4. On HAART for at least 6 months with less than 50 copies/ml of plasma HIV-1 RNA at two determinations over 3 months 5. Current CD4 count above 400 6. CD4 count nadir \>200 7. Viral isolate pre ART available is preferable but not mandatory 8. Willing to consider stopping HAART repeatedly. 9. Willing to conform to a low alcohol intake (maximum of one glass per day) 10. Able to tolerate didanosine and hydroxyurea 11. Willing to change their HAART to exclude NNRTI and stavudine 12. Able to give informed consent 13. Availability for follow-up for planned duration of the study
Exclusion criteria
1. Patients with ongoing infection(s) other than HIV. 2. Prior or current pancreatitis or history of alcohol abuse. 3. Ongoing neuropathy and history of more than grade 1 neuropathy. 4. History of mutations to more than one class of anti-retroviral drugs or switched drugs more than once due to failure. 5. Sun or solarium exposure at the immunizing sites one month before or during the trial. 6. Cortisone treatment, systemic or local at the immunizing sites, one month before or during the trial. 7. Patients with signs of autoimmune diseases 8. Patients with creatinine \> 2mg/dl, Hb \< 12g/dl, leukocytes \< 3,000ul, platelets \<150,000/ul and LFT \> 5x upper limit of normal 9. Patients on any immune modulating or investigational drug 10. Anamnestic allergy to kanamycin, plasmid gene products
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and feasibility | — | The safety and feasibility of dermal HIV-1 DNA vaccination will be evaluated by recording all medical events. They will be graded as to their seriousness, severity and relationship to the immunization. Plasma HIV-1 RNA levels and T-cell levels will be closely monitored. In addition to this the patient's individual experience and quality of life will be assessed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Treatment effects | — | To evaluate whether dermal HIV-1 DNA vaccination can prolong periods without treatment in HIV-infected individuals. This will be evaluated by structured treatment interruption with close monitoring of HIV viral load and CD4+ T cell counts |
Countries
Sweden
Outcome results
None listed